Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnaBoNT-A vs Oxybutynin in SCI Patients with Neurogenic Detrusor Overactivity
NCT01050114Phase 3Unknown
- Start
- Aug 2013
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in neurogenic detrusor overactivity (NDO) (2 arms). Primary endpoint: Safety and Efficacy of OnaBoNT-A vs Oxybutynin at 12 weeks. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT01050114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01050114.